Summary

The fact that a cosmetic ingredient demonstrates a particular activity does not automatically mean that a finished product containing that ingredient has the same efficacy. When reviewing supplier documentation, it is necessary to confirm whether the test sample, actual active concentration, test matrix, evaluation endpoint, and intended label wording fall within the same applicable scope. This helps prevent ingredient-level experimental results from being overstated as finished-product efficacy claims.

What Is Efficacy Claim Evidence Matching?

Efficacy claim evidence matching means that the ingredient identity, actual use concentration, test conditions, evaluation subject, and label wording have an explainable and traceable relationship.

Whether an efficacy report can support finished-product labeling cannot be determined solely by whether the report shows that the material is “effective.” It is also necessary to identify whether the tested material was:

• A single active substance;
• A formulated ingredient blend;
• A laboratory test formulation;
• Or the final marketed product.

Whenever the test material, concentration, formulation, or evaluation endpoint changes, the extent to which the original conclusion supports the finished-product label may also change.

In vitro data, mechanism-of-action studies, and ingredient test reports supplied by the manufacturer can help explain an ingredient’s potential function and guide formulation development. However, they cannot be converted directly into label claims such as “repairing,” “soothing,” “anti-wrinkle,” or “hypoallergenic” without considering the actual conditions of the finished product.

Efficacy Evidence Must Meet Four Boundaries

Material Boundary: Is the Test Sample Equivalent to the Commercial Ingredient?

The first step is to confirm whether the sample used in the efficacy study is the same material as the product being purchased.

The following information should be checked:

• Trade name and product code;
• INCI name or other applicable ingredient name;
• Whether the material is a single substance, extract, solution, or formulated blend;
• Active substance, carrier, solvent, and preservative system;
• Sample batch number and document version;
• Whether the test sample and commercial batches are manufactured using the same process.

For example, a supplier may conduct an in vitro study using a high-purity active substance, while the commercial product is a formulated liquid containing carriers, solvents, and preservatives. Although the product names may be similar, the actual active concentration and formulation behavior may be different.

Changes in botanical source, extraction part, extraction solvent, or standardization method should also not be regarded as covered by the original efficacy data solely because the INCI name remains unchanged.

Concentration Boundary: Does the Test Concentration Represent the Actual Concentration in the Finished Product?

The “test concentration” stated in an efficacy report must be converted into the actual concentration of the active substance in the finished product.

The basic relationship is:

Actual active concentration in the finished product = Ingredient addition level × Active substance proportion in the ingredient

For example, if a formulated ingredient is added to the finished product at 2% and the target active substance accounts for 5% of the ingredient, the actual concentration of that active substance in the finished product is:

2% × 5% = 0.1%

If the supplier’s efficacy study used 1% of the pure active substance, the test concentration is ten times the actual concentration in the finished product. The report may still be useful for explaining the mechanism of action or screening formulation options, but it generally cannot support a finished-product efficacy claim of the same strength without further verification.

The following values must be distinguished during concentration review:

• Overall ingredient addition level;
• Active substance content;
• Marker compound content;
• Dry matter content;
• Extract ratio;
• Conversion between concentrate and diluted solution.

A “recommended use level of 1%–5%” also does not mean that every concentration within this range has been validated for efficacy. The recommended level may be based on solubility, stability, or formulation experience rather than efficacy testing.

Condition Boundary: Do the Test Conditions Represent the Actual Use Scenario?

The same ingredient may perform differently in an aqueous solution, simple gel, emulsion, ointment, or surfactant-based system.

The following factors may alter the ingredient’s actual performance in the finished product:

• Formulation pH;
• Dissolution or dispersion state;
• Emulsification system;
• Preservative system;
• Electrolyte content;
• Heating and manufacturing process;
• Interactions with other active ingredients;
• Packaging and storage conditions;
• Leave-on or rinse-off application;
• Application area and frequency of use.

Activity observed in an in vitro cell study also cannot be directly equated with the ingredient reaching the same site of action in an actual formulation. Stability, release behavior, skin contact time, and bioavailability in the finished product can all affect the final result.

Wording Boundary: Does the Label Wording Exceed the Report Conclusion?

The report conclusion and label wording should have a similar level of strength and a comparable scope of application.

“Changes in relevant indicators were observed under specific conditions” cannot be expanded directly into “comprehensively improves skin problems.” Likewise, “helps improve the appearance of fine lines” cannot automatically be rewritten as “reverses skin aging.”

The more specific and stronger the label claim, the more specific the supporting evidence generally needs to be.

The EU common criteria for cosmetic claims require claims to be truthful, supported by adequate evidence, honest, and fair, and they should not mislead consumers by exaggerating ingredient properties. China’s cosmetic efficacy claim framework also requires relevant claims to be supported by corresponding scientific evidence. In the United States, a product’s regulatory status is determined by its intended use, and claims relating to the treatment or prevention of disease or affecting the structure or function of the body may cause the product to be regulated as a drug.

Why Ingredient Efficacy Data Cannot Be Converted Directly into Finished-Product Label Claims

Supplier documentation often presents mechanism-of-action information, experimental findings, and marketing statements in the same document. However, these three types of information do not serve the same evidentiary purpose.

A Mechanism of Action Is Not the Same as Actual Finished-Product Efficacy

If an ingredient demonstrates free-radical-scavenging capacity, enzyme inhibition, or an effect on a biological marker in vitro, this only shows that the ingredient has relevant activity under specific experimental conditions.

Moving from a mechanism of action to actual finished-product efficacy requires the following conditions:

1. The ingredient remains stable in the finished product;
2. The actual active concentration falls within a reasonable range;
3. The formulation does not significantly interfere with its function;
4. The method of use provides sufficient contact time;
5. The finished-product evaluation endpoint corresponds to the intended claim.

Therefore, in vitro antioxidant data cannot be expanded directly into a claim that a product “reverses aging,” and an effect on inflammation-related indicators cannot be converted directly into claims of “treating sensitivity or acne.”

Statistical Significance Does Not Mean Consumers Can Perceive the Effect

Statistical significance in a report indicates that an observed difference is unlikely to be entirely due to random variation. However, it does not independently answer the following questions:

• Is the magnitude of change practically meaningful?
• Can consumers perceive the change?
• Can the result be reproduced in the target population?
• Does the test duration correspond to the product claim?
• Is the result applicable to long-term use?
• Does the label wording exceed the report conclusion?

For example, a statistically significant change in an instrumental parameter does not automatically justify expressions such as “significant improvement,” “intensive repair,” or “complete resolution.”

Ingredient Testing and Finished-Product Testing Serve Different Purposes

Ingredient-level evidence is mainly used to explain:

• The ingredient’s potential mechanism of action;
• Recommended application directions;
• The basis for concentration screening;
• Evaluation endpoints requiring further validation.

Finished-product evidence is used to determine:

• Whether the complete formulation produces the intended effect;
• Whether the actual method of use affects the result;
• Whether the label wording is consistent with the test conclusion;
• Whether the target population is appropriate;
• Whether the intended claim can be used in the target market.

Ingredient documentation may form part of the evidence chain, but it cannot replace an assessment of the complete finished product and the specific label wording.

What Different Types of Evidence Can Support

The closer the evidence is to the final product and actual conditions of use, the more directly it can generally support finished-product labeling. However, even completed finished-product testing cannot support claims beyond the specific scope of the study.

How to Review a Supplier Efficacy Report

Confirm the Test Material Identified in the Report

The report should at least identify:

• Test sample name;
• Product code;
• Sample batch number;
• Composition or active substance content;
• Physical form of the sample;
• Report date and version;
• Testing organization or responsible party.

If the report contains only a marketing trade name without a product code, composition, or sample information, it may be difficult to determine whether the report corresponds to the material currently being purchased.

Check the Test Concentration and Units

The concentration should be clearly expressed as:

• Mass fraction;
• Volume fraction;
• Mass concentration;
• Molar concentration;
• Overall ingredient concentration;
• Or pure active substance concentration.

If a report states that “the concentration used was 1%” without clarifying whether this means 1% of the commercial ingredient or 1% of the target active substance, the result cannot be effectively compared with the finished-product addition level.

For extracts and fermentation-derived ingredients, it is also necessary to determine whether the concentration is calculated on the basis of the original liquid, dry matter, marker compound, or pre-extraction raw material.

Examine the Test Matrix and Control Design

A report suitable for technical assessment should explain the system in which the test was conducted.

The following should be reviewed:

• Blank control;
• Vehicle control;
• Positive control;
• Test formulation containing the ingredient;
• Differences between the test formulation and final finished product.

If the ingredient uses glycerol, water, or another solvent as a carrier, the test design should exclude the possibility that the carrier itself affected the evaluation result.

Determine Whether the Evaluation Endpoint Corresponds to the Intended Claim

The evaluation endpoint should have a reasonable relationship with the intended label wording.

For example:

• Skin hydration or transepidermal water loss measurements may be used to evaluate moisturization or barrier-related performance;
• Skin elasticity, roughness, or wrinkle imaging may support corresponding appearance-improvement assessments;
• Free-radical-scavenging capacity alone is generally insufficient to support an anti-aging effect in humans;
• Antimicrobial testing cannot directly support acne-treatment, anti-infective, or therapeutic wording.

The greater the number of inferential steps between the measured endpoint and the claim, the greater the need for additional finished-product validation.

Review the Population, Duration, and Method of Use

Human evaluations should specify:

• Number of subjects;
• Age range;
• Skin condition;
• Inclusion and exclusion criteria;
• Application area;
• Frequency of use;
• Amount used per application;
• Test duration;
• Environmental conditions;
• Whether a control was included.

Results obtained in a general skin population should not automatically be extended to sensitive skin, children, or other specific groups. Short-term immediate effects should also not be expressed directly as long-term improvement.

Claim Strength Must Match Evidence Strength

Expressions such as “helps improve,” “helps maintain,” and “significantly repairs” do not represent the same level of claim strength. When a report demonstrates only a limited change under defined conditions, the label language should remain within the same boundary.

How Full Composition Affects Active Concentration and Label Assessment

Cosmetic functional ingredients are often formulated products rather than single active substances.

Their composition may include:

• Target active ingredient;
• Water, glycerol, glycols, or oil-based carriers;
• Preservatives;
• Antioxidants;
• Chelating agents;
• Solubilizers;
• Stabilizers;
• pH adjusters;
• Residual substances from extraction or manufacturing.

The complete composition affects three key assessments.

Whether the Actual Active Concentration Can Be Calculated Correctly

If the supplier provides only the recommended addition level without disclosing the active substance or marker compound content, it is not possible to determine whether the effective exposure in the finished product is comparable to the efficacy test conditions.

Whether It Affects the Full Ingredient List and “Free-From” Claims

Carriers, preservatives, fragrance components, or other auxiliary substances may need to be considered during finished-product composition review and label assessment.

Claims such as “no added alcohol,” “preservative-free,” “fragrance-free,” or “free from a certain ingredient” must consider whether the relevant substance is already introduced through a formulated ingredient. The fact that it was not intentionally added during finished-product manufacturing does not necessarily mean it is absent from the final product.

Whether It Changes Safety and Target-Population Assessment

Ingredients used as carriers or stabilizers may also affect:

• Suitability for eye-area or lip products;
• Assessment of products for sensitive skin;
• Total preservative-system load;
• Fragrance allergen management;
• Finished-product irritation potential;
• Formulation stability.

When a supplier cannot publicly disclose the complete percentages, sufficient information should still be made available through confidential documentation, composition ranges, or safety assessment data to allow an appropriate finished-product evaluation.

Minimum Cross-Verification Between Documents

The objective is not to collect as many documents as possible, but to ensure that key information can be cross-verified across product specifications, COAs, TDSs, SDSs, and impurity data.

A COA showing that a batch meets specification does not mean that the batch has completed finished-product efficacy validation. Likewise, the absence of hazard classification in an SDS does not mean the finished product is suitable for every skin type or every use concentration.

Changes That May Make Existing Efficacy Evidence No Longer Applicable

Supplier documents and efficacy reports normally correspond to a specific version of an ingredient. The following changes may require the applicability of the evidence to be reassessed:

• Change in active substance content or standardization range;
• Change in carrier or dilution ratio;
• Change in preservative, antioxidant, or stabilizer;
• Change in botanical species, origin, plant part, or extraction process;
• Change in fermentation strain or production conditions;
• Change in commercial product code;
• Change in a critical test method or specification limit;
• Use of different manufacturing processes for the test sample and commercial batches;
• Color, odor, content, or stability changes caused by storage or transportation deviations;
• Change in label wording, target population, application area, or sales market.

Minor batch-to-batch variation does not necessarily invalidate all existing data, but it is necessary to confirm whether the variation remains within the range covered by the efficacy study.

For natural ingredients standardized using marker compounds, confirming only total solids or appearance is generally insufficient to demonstrate that the functionally relevant composition remains unchanged.

Risk Signals in Efficacy Claim and Label Review

How the Target Market Affects Label Assessment

The same ingredient report may be used as technical information in multiple markets, but it does not establish that the same label wording can be used directly in every market.

China

Cosmetic efficacy claims must be supported by evaluation evidence appropriate to the specific claim category. The review should consider not only whether the ingredient has relevant activity, but also whether the finished product has sufficient scientific support under normal conditions of use. Not all claims require the same evaluation method, and the applicable requirements depend on the product category and specific claim.

European Union

Cosmetic claims must comply with the common criteria of legal compliance, truthfulness, evidential support, honesty, fairness, and informed decision-making. The fact that an ingredient has a specific property does not automatically prove that the finished product has the same property. The product information file must also contain relevant evidence where substantiation of the claimed effect or property is required.

United States

In the United States, particular attention must be paid to the product’s intended use. If the label, website, or promotional materials claim that the product treats or prevents disease, or affects the structure or function of the body, the product may no longer be regulated solely as an ordinary cosmetic. The assessment depends not only on individual words, but also on the overall promotional context.

Possession of a test report, SDS, or supplier declaration does not mean that the product automatically complies with all target-market requirements. The final assessment must still consider the complete formulation, specific claim, and sales region.

Information to Confirm During the RFQ and Sample Stage

Before an ingredient enters formal formulation testing, the RFQ documentation should, where possible, specify:

• Trade name and product code;
• INCI name or applicable target-market name;
• Whether the material is a single ingredient or formulated blend;
• Active substance, marker compound, or dry matter content;
• Recommended use level and its basis;
• Intended actual addition level in the finished product;
• Leave-on or rinse-off application;
• Application area and target population;
• Intended efficacy wording;
• Test sample and sample code used in the efficacy report;
• Test concentration and concentration unit;
• Test matrix and control design;
• Evaluation method, test duration, and main endpoints;
• Whether the report corresponds to the current commercial product;
• Ingredient change-notification mechanism;
• Target sales market;
• Available composition, safety, and efficacy documentation.

This information can reveal clear evidence mismatches during the sample stage, reducing the risk of discovering only after formulation development that the supplier documentation cannot support the intended label.

Scope of Documentation Support Available from ChemicalCell

During the RFQ and sample stages, ChemicalCell can assist in confirming ingredient identity, product specifications, composition ranges, active substance content, batch documentation, and available efficacy and safety documents.

Finished-product efficacy claims and label compliance must still be independently assessed on the basis of the complete formulation, actual conditions of use, evaluation plan, and target market.

FAQ

If an Ingredient Already Has an Efficacy Study, Does the Finished Product Still Need Further Evaluation?

Ingredient studies can support mechanism-of-action assessment, concentration screening, and formulation design. Whether additional finished-product evaluation is required depends on the intended claim, differences between the test sample and the finished product, and target-market requirements. When the ingredient concentration, formulation matrix, method of use, or evaluation endpoint changes, the same conclusion generally cannot be applied directly.

To What Extent Can Supplier Documentation Support Finished-Product Labeling?

Supplier documentation can support ingredient identity, composition, actual active concentration, recommended conditions of use, and ingredient-level efficacy assessment. Final finished-product labeling must also consider the complete formulation, finished-product evaluation, target population, method of use, and sales market. It cannot be determined solely from an ingredient marketing brochure.

Can a Report Still Be Used If the Efficacy Test Concentration Is Higher Than the Actual Active Concentration in the Finished Product?

The report may still be used to explain the mechanism of action or as a reference for formulation screening, but it cannot support a finished-product claim of the same strength without further analysis. The concentration gap, dose–response relationship, test matrix, and the availability of finished-product data or data generated at a concentration closer to actual use must be evaluated.

Document Request and RFQ

After the ingredient name, product code, intended addition level, target efficacy wording, and sales market are provided, the available documentation can be reviewed to determine which conclusions it can support and what additional composition, concentration, or efficacy data may be required before sample validation.

Clarifying evidence requirements during the RFQ stage is more effective for managing development timelines and label-adjustment risks than requesting additional documentation after finished-product labeling has already been finalized.